Ultragenyx Pharma (RARE) Misses Q2 EPS by 16c, beats revenue

Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($2.25), $0.16 worse than the analyst estimate of ($2.09). Revenue for the quarter came in at $108.3 million versus the consensus estimate of $107.1 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
• FedEx (FDX) PT Lowered to $424 at Bernstein SocGen Group